Seventure and Lundbeckfond inject €5m in Enterome

This follows a €1.5m seed round from Seventure Partners (Natixis) and INRA Transfert, completed at an unspecified date.

The fresh funds will allow Enterome to validate its proprietary biomarkers, translate them into medical diagnostics and commercialise them in the US and Europe. The company also plans to initiate industrial partnerships in the pharmaceutical and nutrition fields.

Company
Enterome is currently developing drugs and biomarkers for medical conditions relating to abnormalities of the human intestine's bacterial composition.

Enterome's technology was initially developed at the INRA (Institut National de la Recherche Agronomique) in Jouy-en-Josas. It is targeting diseases such as NASH, type-II diabetes, and inflammatory bowel diseases (Crohn's disease and ulcerative colitis).

Based in Paris, the business currently employs six people.

People
Isabelle de Cremoux led the deal for Seventure Partners. Lundbeckfond Ventures was represented by Johan Kordel. Pierre Belichard is CEO of Enterome.

Advisers
Company - Nixon Peabody, Emmanuelle Porte, Sylvie Hamel (Legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Healthcare
• Early-stage
• France